✦ LIBER ✦

T1145 A Double-Blind, Placebo-Controlled, Dose-Escalation, Safety and Pharmacokinetic Study of MDX-1100, a Fully Human Anti-CXCL10 Monoclonal Antibody, in Healthy Subjects

✍ Scribed by Yellin, Michael; Goldwater, Ronald; Blanset, Diann L.; Cardarelli, Pina M.

Book ID: 122069099
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 167 KB
Volume: 134
Category: Article
ISSN: 0016-5085
DOI: 10.1016/S0016-5085(08)62304-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II, randomized, double-blind, pl

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

✍ Michael Yellin; Igor Paliienko; Andra Balanescu; Semen Ter-Vartanian; Vira Tselu 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB

704 A Phase 1 Open-Label, Single-Dose, D

704 A Phase 1 Open-Label, Single-Dose, Dose-Escalation Study of Mdx-1100, a High-Affinity, Neutralizing, Fully Human Igg1κ Anti-CXCL10 (Ip10) Monoclonal Antibody, in Ulcerative Colitis

✍ Robert Hardi; Lloyd Mayer; Stephan R. Targan; Michael Yellin; Pina M. Cardarelli 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 185 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

A phase 1, randomized, double-blind, pla

A phase 1, randomized, double-blind, placebo-controlled dose-escalating, safety, tolerability, pharmacokinetic, and pharmacodynamic study of oral recombinant human interleukin eleven (O-rhIl-11) in normal healthy subjects

✍ Cotreau, Monette M.; Stonis, Lucille; Schwertschlag, Ullrich S. 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 170 KB

737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND,

737 A PHASE-I, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ESCALATING ORAL DOSES OF GS-9620 IN HEALTHY SUBJECTS

✍ U. Lopatin; G. Wolfgang; R. Kimberlin; D. Turnas; M. Cornprost; G. Chittick; C. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 46 KB

493 Safety Profile and Signal of Efficac

493 Safety Profile and Signal of Efficacy of a Non-Fcr-Binding, Fully Human Anti-Cd3 Monoclonal Antibody in Patients with Moderate to Severe Crohn's Disease- Results of a Phase I/Iia, Double Blind, Placebo-Controlled, Randomized, Dose Escalation Study

✍ Christien J. van der Woude; Pieter C. Stokkers; Ad A. van Bodegraven; Gert A. Va 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 87 KB